Krischan J Hudson - ViiV Healthcare | 人才画像

基本信息

浏览量：4

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Multi-level Considerations for Optimal Implementation of Long-Acting Injectable Antiretroviral Therapy to Treat People Living with HIV: Perspectives of Health Care Providers Participating in Phase 3 Trials

Mantsios Andrea,Murray Miranda,Karver Tahilin S.,Davis Wendy,Galai Noya,Kumar Princy,Swindells Susan,Bredeek U. Fritz,García Rafael Rubio,Antela Antonio,Gomis Santiago Cenoz,Bernáldez Miguel Pascual,Czarnogorski Maggie,Hudson Krischan,Walters Nicki,Kerrigan Deanna

BMC Health Services Research（2021）

引用30浏览0WOS引用

Week 96 efficacy and safety of cabotegravir plus rilpivirine every 2 months in ATLAS-2M Phase IIIb study

Hans Jaeger,Edgar Overton,Gary Richmond,Giuliano Rizzardini,Jaime-Federico Andrade-Villanueva,Rosie Mngqibisa,Antonio Ocampo Hermida,Anders Thalme,Paul Benn,Yuanyuan Wang,Krischan Hudson,David Margolis,Christine Talarico,Kati Vandermeulen,William Spreen

HIV MEDICINE（2021）

引用0浏览0引用

Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

Mantsios Andrea,Murray Miranda,Karver Tahilin S.,Davis Wendy,Margolis David,Kumar Princy,Swindells Susan,Bredeek U. Fritz,García del Toro Miguel,Garcia Gasalla Mercedes,Rubio García Rafael,Antela Antonio,Hudson Krischan,Griffith Sandy,Kerrigan Deanna

AIDS and Behavior（2020）

引用37浏览0WOS引用

1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome

Christine L Talarico,Sterling Wu, Ojesh R Upadhyay,Marty St Clair,Veerle Van Eygen,Krischan J Hudson,Sandy Griffith,Conn M Harrington,Jan van Lunzen,David Margolis,William Spreen

Open forum infectious diseasesno. Supplement_1 (2020): S540-S541

引用0浏览0引用

Identifying Appropriate Candidates for Long-Acting Antiretroviral Therapy: Findings from a Survey of Health Care Providers in the ATLAS-2M Trial

Miranda Murray,Deanna Kerrigan,Krischan J. Hudson, Nicola Walters,Tahilin Sanchez Karver,Andrea Mantsios,Noya Galai

HIV RESEARCH & CLINICAL PRACTICE（2020）

引用8浏览0WOS引用

Feasibility of Implementing Long-Acting Injectable Anti-Retroviral Therapy to Treat HIV: a Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial

Deanna Kerrigan,Miranda Murray,Tahilin Sanchez Karver,Andrea Mantsios,Nicki Walters,Krischan Hudson,Emma Kaplan-Lewis,Federico Pulido, Ayesha Cassim Bassa,David Margolis,Noya Galai

AIDS Research and Human Retroviruses（2020）

引用4浏览0WOS引用

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Ronald D'Amico,Paul Benn,Cynthia C McCoig,Sandy Griffith,Krischan J Hudson,Kenneth Sutton,Conn M Harrington,Sterling Wu,Will Williams,Kai S Hove,Carlos Martin Espanol, E Jane Fricker,Parul Patel,David Margolis

Open forum infectious diseasesno. Supplement_1 (2020): S847-S848

引用1浏览0引用

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine over 48 Weeks

Murray Miranda,Antela Antonio,Mills Anthony,Huang Jenny, MVZ Karlsplatz, HIV Research and Clinical Care Centre,Bernal Enrique,Lombaard Johan,Katner Harold,Walmsley Sharon,Khuong-Josses Marie-Aude,Hudson Krischan,Dorey David,Griffith Sandy,Spreen William,Vanveggel Simon,Shaefer Mark,Margolis David,Chounta Vasiliki

AIDS and behavior（2020）

引用57浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn